Similarly, Zhong et al. also demonstrated that the highly selective covalent ITK and RLK inhibitor PRN694 showed inhibitory activity against T cell leukemia cells through the downregulation of NFAT1, JunB, PLCγ1, and IκBα [52]. This evidence concerns the gene TXK and T-cell leukemia.